STRO
STRO
NASDAQ · Biotechnology

Sutro Biopharma Inc

$16.03
+0.05 (+0.31%)
Financial Highlights (FY 2026)
Revenue
204.80M
Net Income
-381,859,767
Gross Margin
—
Profit Margin
-186.5%
Rev Growth
+14.8%
D/E Ratio
4.05
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 66.9% 66.9%
Operating Margin -154.5% -139.1% 4.4% 4.4%
Profit Margin -186.5% -177.1% 3.9% 3.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 204.80M 178.43M 26.00M 21.24M
Gross Profit — — 17.40M 14.21M
Operating Income -316,479,623 -248,154,435 1.13M 924.7K
Net Income -381,859,767 -299,419,576 1.01M 706.3K
Gross Margin — — 66.9% 66.9%
Operating Margin -154.5% -139.1% 4.4% 4.4%
Profit Margin -186.5% -177.1% 3.9% 3.3%
Rev Growth +14.8% +14.8% +22.0% +10.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 107.13M 107.13M 17.53M 15.15M
Total Equity 26.43M 26.43M 104.75M 96.80M
D/E Ratio 4.05 4.05 0.17 0.16
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -301,840,137 -249,824,124 1.64M 1.18M
Free Cash Flow — — 646.8K 654.2K